NVS•benzinga•
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Summary
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga